Apotex Announces First Quarter 2027 Results

– Canada Delivers 11% Revenue Growth in Q1 – Adjusted EBITDA1 of $259 Million with 31% Margin – Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit Revenue Growth and ~ 30% Adjusted EBITDA Margin – Successfully Completed Upsized IPO and Applied …

